Sigma-1 Receptor Agonists for Neurodegeneration

Sigma-1 Receptor Agonists for Neurodegeneration

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Sigma-1 Receptor Agonists for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Neuroprotection</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Sigma-1 Receptor (SIGMAR1)</td>
</tr>
<tr>
<td class="label">Drug Class</td>
<td>Small molecule agonists</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>Alzheimer's Disease, Parkinson's Disease, ALS, Huntington's Disease, Stroke</td>
</tr>
<tr>
<td class="label">Status</td>
<td>Preclinical and early clinical trials</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Class</td>
</tr>
<tr>
<td class="label">Pridopidine</td>
<td>Small molecule</td>
</tr>
<tr>
<td class="label">Fluvoxamine</td>
<td>SSRI</td>
</tr>
<tr>
<td class="label">Donepezil</td>
<td>ChEI</td>
</tr>
<tr>
<td class="label">SA-4503</td>
<td>Small molecule</td>
</tr>
<tr>
<td class="label">PRE-084</td>
<td>Small molecule</td>
</tr>
</table>

Introduction

Sigma 1 Receptor Agonists For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Mechanism of Action

...

Sigma-1 Receptor Agonists for Neurodegeneration

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Sigma-1 Receptor Agonists for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Neuroprotection</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Sigma-1 Receptor (SIGMAR1)</td>
</tr>
<tr>
<td class="label">Drug Class</td>
<td>Small molecule agonists</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>Alzheimer's Disease, Parkinson's Disease, ALS, Huntington's Disease, Stroke</td>
</tr>
<tr>
<td class="label">Status</td>
<td>Preclinical and early clinical trials</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Class</td>
</tr>
<tr>
<td class="label">Pridopidine</td>
<td>Small molecule</td>
</tr>
<tr>
<td class="label">Fluvoxamine</td>
<td>SSRI</td>
</tr>
<tr>
<td class="label">Donepezil</td>
<td>ChEI</td>
</tr>
<tr>
<td class="label">SA-4503</td>
<td>Small molecule</td>
</tr>
<tr>
<td class="label">PRE-084</td>
<td>Small molecule</td>
</tr>
</table>

Introduction

Sigma 1 Receptor Agonists For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Mechanism of Action

The Sigma-1 Receptor (SIGMAR1) is a chaperone protein located in the endoplasmic reticulum (ER) that plays a critical role in cellular homeostasis. Sigma-1 agonists provide neuroprotection through multiple mechanisms:

Therapeutic Rationale

Alzheimer's Disease

• Sigma-1 receptors regulate Aβ-induced ER stress
• Agonists reduce Aβ toxicity in cellular models
• Improve synaptic function and memory in AD models

Parkinson's Disease

• Protect dopaminergic neurons from oxidative stress
• Reduce α-synuclein toxicity
• Improve mitochondrial function

ALS

• Sigma-1 mutations cause juvenile ALS
• Agonists compensate for loss-of-function
• Protect motor neurons

Huntington's Disease

• Reduce mutant huntingtin toxicity
• Improve mitochondrial function
• Reduce ER stress

Stroke

• Reduce ischemic damage
• Protect against excitotoxicity
• Improve outcomes in animal models

Drug Candidates

Pridopidine (Clinical Development)

Pridopidine is the most advanced Sigma-1 receptor agonist for neurodegeneration:

Huntington's Disease (Phase 3 - PRIDE-HD)

• Mechanistic study showed Sigma-1 receptor activation
• Potential disease-modifying effects
• Good safety and tolerability profile
• Primary endpoint: Motor function (mMS)

ALS (Phase 2)

• Open-label extension study ongoing
• Biomarker studies showing neuroprotection
• Combined Sigma-1 and dopamine D2 activity

Combination Approaches

• Sigma-1 agonists + acetylcholinesterase inhibitors
• Sigma-1 agonists + memantine
• Sigma-1 agonists + antioxidants
• Sigma-1 agonists + anti-aggregates

Challenges and Limitations

Selectivity: Many drugs have multiple targets

BBB Penetration: Variable brain penetration

Dosing: Optimal dosing unclear

Efficacy: Human data limited

See Also

• SIGMAR1 Gene - Gene Page
• [ER Stress Pathway](/mechanisms/er-stress-pathway)
• [Mitochondrial Dysfunction Pathway](/mechanisms/mitochondrial-dysfunction)
• [Alzheimer's Disease Treatment

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [ClinicalTrials.gov](https://clinicaltrials.gov/)

Background

The study of Sigma 1 Receptor Agonists For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

References

[Maurice T, Su TP, "The pharmacology of sigma-1 receptors." Pharmacol Ther (2009)](https://pubmed.ncbi.nlm.nih.gov/19619584/)

[Nguyen L, et al, "Sigma-1 receptor agonists as therapeutic drugs for ALS." Expert Opin Investig Drugs (2021)](https://pubmed.ncbi.nlm.nih.gov/33886347/)

[Francardo V, et al, "Sigma-1 receptor agonists in Parkinson's disease." Neuropharmacology (2019)](https://pubmed.ncbi.nlm.nih.gov/31051136/)

[Ryskamp D, et al, "Sigma-1 receptor protects from Alzheimer's disease." J Alzheimers Dis (2019)](https://pubmed.ncbi.nlm.nih.gov/31594233/)

[Sahlholm K, et al, "Pridopidine for Huntington's disease." Expert Opin Pharmacother (2020)](https://pubmed.ncbi.nlm.nih.gov/32452623/)

[Ghadiri T, et al, "Sigma-1 receptor in stroke and neuroprotection." Stroke (2020)](https://pubmed.ncbi.nlm.nih.gov/32673526/)

[Mori T, et al, "Sigma-1 receptors in neurodegenerative diseases." Adv Exp Med Biol (2020)](https://pubmed.ncbi.nlm.nih.gov/32072892/)

[Woeffle K, et al, "Fluvoxamine and sigma-1 receptors." Psychopharmacology (Berl) (2021)](https://pubmed.ncbi.nlm.nih.gov/33559721/)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
• [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
• [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
• [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
• [Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2
• [Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
• [Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style="color:#81c784;font-weight:600">0.75</span> · Target: TFRC
• [Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7

Related Analyses:

• [Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) &#x1f504;
• [Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) &#x1f504;
• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;
• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;
• [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;